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Abstract: Peptidoglycan recognition proteins (PGLYRPs) are a family of pattern recognition receptors
(PRRs) that are able to induce innate immune responses through their binding to peptidoglycan
(PGN), lipopolysaccharide, or lipoteichoic acid, or by interacting with other PRR-ligands. Recently,
progress has been made in understanding the immunobiology of PGLYRPs in human and mice,
however, their functions in livestock animals have been less explored. In this study, we characterized
the expression patterns of PGLYRPs in porcine intestinal epithelial (PIE) cells and antigen-presenting
cells (APCs) and their modulation by the interactions of host cells with PRR-ligands and non-viable
immunomodulatory probiotics referred to as paraimmunobiotics. We demonstrated that PGLYRP-1,
-2, -3, and -4 are expressed in PIE cells and APCs from Peyer’s patches, being PGLYPR-3 and -4 levels
higher than PGLYRP-1 and -2. We also showed that PGLYRPs expression in APCs and PIE cells can
be modulated by different PRR agonists. By using knockdown PIE cells for TLR2, TLR4, NOD1, and
NOD2, or the four PGLYRPs, we demonstrated that PGLYRPs expressions would be required for
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activation and functioning of TLR2, TLR4, NOD1, and NOD2 in porcine epitheliocytes, but PGLYRPs
activation would be independent of those PRR expressions. Importantly, we reported for the first
time that PGLYRPs expression can be differentially modulated by paraimmunobiotic bifidobacteria
in a strain-dependent manner. These results provide evidence for the use of paraimmunobiotic
bifidobacteria as an alternative for the improvement of resistance to intestinal infections or as
therapeutic tools for the reduction of the severity of inflammatory damage in diseases in which a role
of PGLYRPs-microbe interaction has been demonstrated.
Keywords: paraimmunobiotics; peptidoglycan recognition protein; bifidobacteria; innate immunity;
porcine intestinal epitheliocytes; porcine antigen-presenting cells
1. Introduction
The innate immune system provides the first line of defense against invading microorganisms
employing different strategies to discriminate non-self-structures from self-molecules. This function is
mediated by germ-line encoding pattern recognition molecules called pattern recognition receptors
(PRRs) that recognize the conserved pathogen-associated molecular patterns (PAMPs) present in
microorganisms but absent in the host, such as lipopolysaccharides (LPS) of Gram-negative bacteria,
lipoteichoic acids (LTA) of Gram-positive bacteria or peptidoglycan (PGN) of both Gram-positive
and -negative bacteria [1]. Peptidoglycan (PGN) is a peptide-cross-linked sugar polymer that is an
essential cell wall component of virtually all bacteria [2]. Although the overall structure of PGN
from different bacteria is similar, there are backbone and crosslinking modifications that increase the
diversity among bacterial species. The innate immune system is able to sense intact PGN as well as
PGN fragments using numerous PRRs that are secreted, expressed intracellularly or located on the
cells’ surface. PGN and its fragments are primarily recognized by peptidoglycan recognition proteins
(PGLYRPs or PGRPs), a novel family of PRR, which were initially named according to their ability
to bind PGN [3,4]. In addition, PGLYRPs can also sense the ligands of other PRRs including toll-like
receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-containing proteins [2,5].
Structurally all PGLYRPs have at least one C-terminal PGLYRP domain, which enables the
interaction with bacterial PGN, and is homologous to the bacteriophage and to the prokaryotic
PGN-lytic type 2 amidases [6,7]. PGLYRPs are conserved from insect to mammals and at least four
members (PGLYRP-1, PGLYRP-2, PGLYRP-3, and PGLYRP-4) with distinct expression patterns have
been identified in humans [3], mice [8], rats [9], and cattle [10]. Mammalian PGLYRP-1 is highly
expressed in neutrophil’s granules, intestinal M cells [1], and also expressed as a serum dimeric
protein [11]. PGLYRP-2 is an N-acetyle-muramoyl-L-alanine amidase, which can cleave the peptide
from the glycan chain of PGN and is constitutively expressed in the liver, intestinal epithelial cells
(IECs) and secreted into blood [12]. Studies in humans demonstrated that PGLYRP-3 and PGLYRP-4
proteins are selectively expressed in tissues that come in contact with the environment including
the skin epidermis, sebaceous glands, the corneal epithelium of the eye, and the mucus-secreting
cells of the main salivary gland [13]. PGLYRP-3 and PGLYRP-4 have also been detected in epithelial
cells of the gastrointestinal tract of humans [9] and mice [7]. Despite the fact that pigs are important
livestock animals and are also considered the most approximate animal model for human diseases, the
expressions of PGLYRPs in porcine tissues and cells has been less explored. Therefore, the knowledge
of the location where porcine PGLYRPs are expressed and stored, and how they are activated and
regulated are important points of research.
Previous studies have reported the antibacterial and immunomodulatory properties of human and
mouse PGLYRPs and their expression in the gastrointestinal tissues [14,15]. PGLYPRs have evolved a
variety of mechanisms to control the host’s mucosal interactions with mutualistic, commensal and
pathogenic microorganisms to benefit the host [16,17]. Moreover, it was reported that mammalian
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PGLYRPs influence host-microbial interactions through their peptidoglycan-hydrolytic, bactericidal,
and immunomodulatory properties [5,18]. Deficiencies in individual PGLYRPs can cause significant,
but not identical, changes in gut normal microbiota and mucosal inflammatory responses [19,20].
In the past decade, the study of the cellular and molecular interactions of the intestinal
microbiota members with epithelial and immune cells has clearly demonstrated the influence of
those microorganisms on the host’s homeostasis [21]. Numerous benefits conferred by the microbiota
have been characterized and in addition, bacterial strains with particular beneficial abilities have been
selected for the development of products that are able to improve the health of the host. In this regard,
probiotic bacteria have been proven to be efficient for ameliorating intestinal inflammation, improving
epithelial barrier function, stimulating the mucosal immune system and preventing pathogenic
microbial growth and colonization [22–28].
Members of the genus Bifidobacterium are among the first microbes to colonize the human
gastrointestinal tract and are believed to exert positive health benefits on their host [23]. Several studies
demonstrated that bifidobacteria strains, including Bifidobacterium longum subsp. longum BB536 and
Bifidobacterium breve M-16V, as well as non-viable immunomodulatory bifidobacteria referred to as
paraimmunobiotic bifidobacteria, are able to improve the resistance against respiratory and intestinal
infections [24,25] and to reduce the severity of symptoms in inflammatory-mediated diseases [26–28].
Although some advances have been made in the understanding of the cellular and molecular interactions
between paraimmunobiotic bifidobacteria with the host [29], their specific role in the regulation of
PGLYRPs expression has not been explored.
In this work, we demonstrated that four PGLYRPs (PGLYRP-1, PGLYRP-2, PGLYRP-3, and
PGLYRP-4) are expressed in the gastrointestinal tissues of pigs, especially in IECs and antigen-presenting
cells (APCs). We showed that porcine PGLYRPs expression in APCs and IECs can be modulated
by interactions in different PRR agonists. Importantly, we demonstrated for the first time that
PGLYRPs expression in porcine APCs and IECs could be differentially modulated by paraimmunobiotic
bifidobacteria, which sheds the light on immunobiotic mediated health benefits.
2. Materials and Methods
2.1. Ethics Statements, Collection, and Preparation of Tissue Samples
The study was carried out in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the Guidelines for Animal Experimentation of Tohoku
University, Sendai, Japan. The present study was approved by the Animal Research and Animal Care
Committee of the Tohoku University (2013 Noudou-017, 6th March 2013) and all efforts were made to
minimize suffering.
Porcine tissues (spleen, mesenteric lymphoid nodes, and Peyer´s patches (PPs) from ileum and
jejunum) were obtained from healthy adult LWD swine (n = 16; genotype 1/4 Landrace, 1/4 Large
White, 1/2 Duroc) provided by the Miyagi Prefecture Animal Husbandry (Miyagi, Japan). Tissue
sections were cut into 3 × 3 mm squares and treated with 1 mL of RNAlater® Stabilization Solution
(ThermoFisher Scientific, Chicago, IL, USA) and were transferred into round bottom propylene tubes
(Falcon 2006, Becton Dickinson, Lincoln, NJ, USA) containing 1 mL of TRIzol (Invitrogen, Carlsbad,
CA, USA) and stored at −80 ◦C.
2.2. Gene Expression Analysis
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and treated with
gDNA Wipeout Buffer (Qiagen, Tokyo, Japan). All cDNAs were synthesized using a Quantitect reverse
transcription (RT) kit (Qiagen, Tokyo, Japan), according to the manufacturer’s recommendations.
Real-time quantitative PCR was carried out using a 7300 real-time PCR system (Applied Biosystems,
Warrington, UK). The qRT-PCR was performed using a 7300 real-time PCR system (Applied Biosystems,
Warrington, UK) and the TaqMan® gene expression assay kit (Life Technologies, New York, NY, USA),
Cells 2019, 8, 891 4 of 22
TaqMan® Universal Master Mix II, with UNG (Applied Biosystems, Warrington, UK). The PCR cycling
conditions were 2 min at 50 ◦C, followed by 10 min at 95 ◦C, and then 40 cycles of 15 s at 95 ◦C, 1 min at
60 ◦C. The reaction mixtures contained 2.5 µL of sample cDNA, 1 µL gene expression assay, and 10 µL
TaqMan® Universal Master Mix II, with UNG, and 6.5 µL distilled water. According to the minimum
information for publication of quantitative real-time PCR experiments guidelines, β-actin was used as a
reference housekeeping gene because of its high stability across various porcine tissues [30,31]. We used
DNA plasmids designed by GeneArt StringsTM as standards for qPCR. Plasmids were designed in the
100 bp before and after from the center of the assay location (Total 200 bp). Sequences of the DNA
plasmids used are shown in Supplementary Table S1.
2.3. Immunohistochemical Analysis
Fresh ileal PPs (n = 3) were obtained as described before, washed with phosphate-buffered saline
(PBS), cut into small pieces (5 × 10 mm), and fixed in Zamboni’s fixative (Wako, Tokyo, Japan) for 16 h at
4 ◦C. The fixed tissues were washed for 24 h with 1% gum arabic in 0.1 M phosphate buffer containing
8% sucrose and for an additional 24 h with the same solution containing 16% sucrose. Samples
were immersed in TISSUE TEK O.C.T. compound (Sakura Finetechnical, Tokyo, Japan) and quickly
frozen in a dry ice/acetone bath. Cryostat sections (10 µm) were prepared from the frozen tissues.
The sections were incubated with blocking one histo (Nacalai Tespue Inc., Kyoto, Japan) to block
non-specific binding sites. After removal of the blocking solution, sections were incubated for 16 h at
4 ◦C in a humidified chamber with 1:1000 anti-porcine PGLYRP-3 polyclonal antibody (#COP-080060,
Cosmo Bio, Tokyo, Japan) or 1:1000 anti-porcine PGLYRP-4 polyclonal antibody (#COP-080061, Cosmo
Bio). After washing with PBS, sections were incubated for 60 min with 1:1000 Alexa 488-conjugated
goat anti-rabbit IgG F(ab’)2 (ThemoFisher Scientific, Yokohama, Japan). Double immunostaining
for pan-cytokeratin, and either PGLYRP-3 or PGLYRP-4, was also performed using 1:2000 anti-pan
cytokeratin monoclonal antibody (clone C-11; Sigma-Aldrich, St. Louis, MO, USA) followed by 1:1000
Alexa 546-conjugated goat anti-mouse IgG F(ab’)2 (ThemoFisher Scientific, Yokohama, Japan). Then,
samples were washed three times with PBS and stained with DAPI (Dojindo Laboratories, Kumamoto,
Japan) to detect nuclei. Finally, the tissue sections were washed three times with PBS, mounted in
ProLong Gold (ThemoFisher Scientific, Yokohama, Japan), and observed under an FSX100 microscope
(Olympus, Tokyo, Japan). Control experiments were performed by omitting primary antibodies.
2.4. Flow Cytometer-Based Analysis of PGLYRPs Expression in Porcine APCs from Ileal Peyer´s Patches
Expression levels of PGLYRPs in APCs from ileal PPs of adult swine were determined by flow
cytometry. APCs were prepared according to our previous studies with some modifications [28,29].
Briefly, PPs were cut into fragments and then smoothly pressed through a nylon mesh, and washed with
complete RPMI medium supplemented with 10% FCS. A hypotonic solution (0.2% NaCl, Sigma, Tokyo,
Japan) was used to eliminate residual red cells and, a rescue was performed with an equal volume of a
hypertonic solution (1.5% NaCl). This mononuclear cell suspension contains a mixed population of T
(CD4+ and CD8+), B (CD21+), and APCs (CD4-CD8-MHC-II+) [29]. For the detection of cell surface
and intracellular PGLYRPs in different populations APCs (CD172ahighCD11R1+, CD172alowCD11R1+,
or CD172alowCD11R1low cells) the following primary antibodies were used: anti-porcine CD172a-PE
SWC3 IgG1 (Southern Biotech, Tokyo, Japan), and anti-porcine CD11R1-unlabeled IgG1 (AbD Serotec,
Boston, USA). Unlabeled monoclonal antibodies were detected by the following secondary antibodies:
anti-mouse IgG1-PerCP/Cy5.5 (Bio Legend, San Diego, CA, USA) and anti-rabbit IgG Alexa Fluor
488. Isotype controls were obtained by incubating cells with isotype mouse IgG1-PE or IgG1-PerCP
antibodies (eBioscience, San Diego, CA, USA). The expression of PGLYRP-1 and -2 in APCs was
analyzed by using antisera originally obtained from immunized rabbits. The expression of PGLYRP-3
and -4 were analyzed by using the polyclonal antibodies mentioned above. Cells were collected,
washed twice with washing buffer (2% FCS, 0.01% NaN3/PBS, Sigma, Tokyo, Japan) and live cell
counts were adjusted to 1 × 106 cells/tube. Immune cells were resuspended and labeled with primary
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and secondary antibodies for detection of surface expression of CD172a, CD11R1, and PGLYRP-1, -2,
-3 or -4. In another set of experiments, cells were permeabilized with the BD cytofix-cytoperm kit
(BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions and then labeled
with primary anti-mouse PGLYRPs and secondary antibodies for detection of intracellular PGLYRPs.
Analysis of the stained cells was performed using BD Accuri™ C6 Flow Cytometer (BD, Franklin
Lakes, NJ, USA) equipped with C6 software. FlowJo software (Tree star, Ashland, OR, USA) was used
for the data analysis.
2.5. Analysis of PGLYRP Expressions in APCs from Peripheral Blood
Porcine monocyte-derived dendritic cells (MoDCs) were generated as previously described [32].
Briefly, porcine monocytes were obtained from freshly collected porcine peripheral blood by a density
gradient centrifugal method (1800 rpm, 20 min, 20 ◦C) with Lympholyte-mammal (Cedarlane, Hornby,
ON, Canada). Cells were suspended in RPMI and plated (1 × 107 cells/mL per well) into 12-well plates
(Corning, Brumath, France) in RPMI-1640 supplemented with 2% FCS, 1% Streptomycin/Penicillin,
and incubated two hours. Non-adherent cells were removed and remaining cells were incubated with
RPMI supplemented with 10 µL/well of porcine GM-CSF (20 ng/mL) and 10 µL/well of porcine IL-4
(20 ng/mL). Fresh medium was renewed every 2 days. After 5 days of culture, cells were incubated with
RPMI medium supplemented with GM-CSF, IL-4, and 5 µL/well of LPS (200 µg/mL) in order to induce
differentiation of MoDC. The qRT-PCR was performed to quantify the expression of PGLYRPs mRNAs
in porcine MoDCs. qRT-PCR was carried out with using Platinum SYBR Green qPCR SuperMix UDG
with ROX (Invitrogen, Carlsbad, CA, USA). The primers used in this study are listed in Supplementary
Table S2.
2.6. Analysis of PGLYRPs Expression in PIE Cells
The PIE cell line, originally derived from intestinal epithelia from an unsuckled neonatal
swine [33,34], was maintained in DMEM (Invitrogen Corporation, Carlsbad, CA, USA) supplemented
with 10% FCS, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 ◦C in an atmosphere of 5% CO2.
PIE cells were passaged by treatment with a sucrose/EDTA buffer for 4 min, detached using 0.04%
trypsin in PBS, and then plated at a density of 3 × 104 cells/well in a type I collagen-coated (SUMILON,
Tokyo, Japan) at 37 ◦C in an atmosphere of 5% CO2. PIE cells were cultured in DMEM supplemented
with 10% FCS and passaged every 3 or 4 days. In the present study, PIE cells between the 20th and
35th passages were used in experiments. In order to quantify the expression of PGLYRPs mRNA
and protein, qRT-PCR and immunohistochemistry analysis were performed in PIE cells according to
methods described earlier.
2.7. Paraimmunobiotic Bifidobacteria
Immunobiotic bifidobacteria strains were provided by Morinaga Milk Industry Co. Ltd. (Zama,
Japan). B longum subsp. longum BB536 and B. breve M-16V were grown in Man-Rogosa-Sharpe (MRS)
broth and agar (Difco, Detroit, MI, USA) supplemented with 0.05% (w/v) cysteine (Sigma, Tokyo, Japan)
and incubated at 37 ◦C for 16 h under anaerobic conditions (AnaeroGen; Oxoid, Basingstoke, UK).
Cultures were then centrifuged at 19,000× g for 10 min, and bifidobacteria were washed with PBS and
resuspended in DMEM at the appropriate concentrations [35]. The bifidobacteria were heat-killed at
65 ◦C for 30 min to obtain the paraimmunobiotics and stored at −80 ◦C until further use.
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2.8. Modulation of PGLYRPs Expression in MoDCs and PIE cells by Paraimmunobiotic Bifidobacteria and/or
PRRs Ligands
MoDCs were seeded at 1 × 107 cells/12-well type I collagen-coated plates (Iwaki, Tokyo, Japan)
and cultured for 5 days and stimulated with TLR2, TLR4, NOD1, or NOD2 ligands for 12 h. MoDCs
(1 × 107 cells/12 well) were also stimulated with the two paraimmunobiotic bifidobacteria individually
(5 × 107 CFU/mL) for 6h. PIE cells were seeded at 3 × 104 cells/12-well type I collagen-coated plates
(Iwaki, Tokyo, Japan), cultured for 5 days and then stimulated with TLR2, TLR3, TLR4, TLR5, TLR7,
TLR8, TLR9, NOD1, or NOD2 ligands for 12 h (Supplementary Table S3). PIE cells were stimulated
with the two paraimmunobiotic bifidobacteria individually (5 × 107 CFU/mL) for 6 h. In another set
of experiments, PIE cells were seeded at 3 × 104 cells/12-well plate on type I collagen-coated plates
(Iwaki), cultured for 3 days and treated with paraimmunobiotic bifidobacteria (5 × 107 cells/mL) for
48 h. Then, each well was washed vigorously with medium at least three times to eliminate bacteria,
and cells were stimulated with different PRRs ligands (TLR2, TLR4, NOD2) for 12 h. The mRNA
expression of PGLYRPs was evaluated by qRT-PCR.
2.9. PRRs Knockdown in PIE Cells
For RNA interference, PIE cells were seeded (3 × 104 cells/well) in 12-well type I collagen-coated
plates (Iwaki, Tokyo, Japan) and cultured for 5 days. Then cells were transfected with specific short
interfering RNAs (siRNAs) for TLR2 (6.25 pmol), TLR4 (6.25 pmol), NOD1 (12.5 pmol), or NOD2
(12.5 pmol) using lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) for 12 h. Primers used for
TLR2, TLR4, NOD1, and NOD2 gene knockdown in PIE cells are listed in Supplementary Table S4.
Stealth RNAiTM siRNA Negative Control Med GC Duplex #3 (#12935-113, Invitrogen, Carlsbad, CA,
USA) was used as control. qRT-PCR was performed to examine the inhibition of PRRs expression in
knockdown cells. In a second set of experiments, PIE cells were seeded at 3 × 104 cells/12-well type
I collagen-coated plates (Iwaki, Tokyo, Japan) and cultured for 5 days. After changing the medium,
cells were transfected with siRNAs for 12 h. Then, the PRR knockdown cells were stimulated with
paraimmunobiotic bifidobacteria for 6 h to evaluate the regulation of PGLYRP expressions.
2.10. Analysis of Intracellular Ca2+ flux in PRRs Knockdown PIE Cells
Evaluation of intracellular calcium flux by PRRs ligands in TLR2-, TLR4-, NOD1-, and
NOD2-knockdown PIE cells were performed according to the method of Murofushi et al. [36],
with some modifications. Briefly, the knockdown cells (1 × 105 cells/100 µL medium) were plated on
96-well Cell Culture Clear Bottom Black Plates (Corning Inc., New York, NY, USA) at 37 ◦C for 24 h.
After the careful elimination of the medium by aspiration, 100 µL lording buffer of Calcium Kit-Fluo 4
(Dojindo Laboratories, Tokyo, Japan) was added and incubated at 37 ◦C for 1 h. The medium was
then replaced by 100 µL of the recording medium. The dye-stained cells were washed with PBS and
stimulated with 10 µL (1 mg/mL) of LTA, LPS, DAP, or MDP by the dropping system in a fluorescence
spectrophotometer (ARVOTM X3, PerkinElmer Inc., Billerica, MA, USA). The fluorescence intensity
was recorded up to 140 s after stimulation.
2.11. PGLYRPs Knockdown in PIE Cells
For the generation of PGLYRP-1-, PGLYRP-2-, PGLYRP-3-, and PGLYRP-4-knockdown cells, PIE
cells were seeded at 3 × 104 cells/12-well type I collagen-coated plates, and cultured as described
earlier in section “PRRs knockdown in PIE cells”. Cells were transfected with specific siRNAs for
PGLYRP-1, -2, -3 or -4 (26.6 pmol). Primer sets used for PGLYRPs gene knockdown in PIE cells
are listed in Supplementary Table S5. Stealth RNAiTM siRNA Negative Control Med GC Duplex
#3 (#12935-113, Invitrogen, Carlsbad, CA, USA) was used as control. The qRT-PCR was performed
by TaqMan probe method with corresponding primers for PGLYRP-1, -2, -3, and -4 to examine the
inhibition of PGLYRPs expressions in knockdown cells. PGLYRP knockdown PIE cells were stimulated
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with paraimmunobiotic bifidobacteria for 6 h and qRT-PCR was used to evaluate the expression of
TLR2, TLR4, NOD1, and NOD2.
2.12. Statistical Analysis
The results are shown as means ± standard deviation obtained from three independent
experiments (n = 6). The qRT-PCR raw data were log-transformed followed by normality check
by Kolmogorov-Smirnov test and convergence by clubs rejection test. Data were corrected for the
non-stimulated control to become 1.0. One-way ANOVA was performed in GraphPad prism v5.1
followed by calculating the Fisher’s least significant difference for multiple mean comparisons were
defined as significant at p < 0.05 or p < 0.01.
3. Results
3.1. Expression Patterns of PGLYRPs in Porcine Tissues
In a previous study, we cloned and characterized porcine PGLYRP-3 and PGLYPR-4 [15]. Our
qRT-PCR-based expression analysis revealed that porcine PGLYRP-3 and -4 are strongly expressed
in the digestive tract of newborn and adult pigs. We also constructed transfected cell lines in order
to explore the subcellular distribution of porcine PGLYRP-1 to -4. Results indicated that porcine
PGLYRP-1, -3, and -4 are secreted from cells while PGLYRP-2 and PGLYRP-3 are strongly and weakly
expressed on the cell surface, respectively [15]. However, quantitative comparisons of tissue-specific
expression of the four porcine PGLYRP genes and the confirmation of their expression at the protein
level have remained elusive. Therefore, in the present study, we first aimed to evaluate the expression
of the four porcine PGLYRPs in Peyer´s patches (PP) by using qRT-PCR and immunofluorescence.
The expression of porcine PGLYRPs in the spleen was set as reference (as 1.00) and compared with
those expressed in ileal PP, jejunal PP, and mesenteric lymph nodes (MLN) (Figure 1A). PGLYRP-2, -3,
and -4 were detected in both ileal and jejunal PPs while the expression of PGLYRP-1 in those tissues
was lower than in the spleen. PGLYRP-1, -3, and -4 were detected in MLN while PGLYRP-2 was weakly
expressed in this tissue (Figure 1A).
3.2. Immunohistochemical Localization of PGLYRP Proteins in the Porcine Tissues
Immunofluorescence studies were performed to evaluate the expression of PGLYRP-3 and -4
proteins in porcine ileal PPs (Figure 1B,C). Both PGLYRPs (green fluorescence) were expressed in not
only the follicle-associated epithelia but also in dendritic-like cells located beneath the epithelium
(Figure 1B,C).
In addition, PGLYRP-3 or -4 expressing cells were found in the lymphoid follicles. These
results would indicate that PGLYRP-3 and -4 are expressed in porcine IECs and APCs. Then, we
performed additional experiments in IECs and APCs to demonstrate the expression of PGLYRPs in
those cell populations.
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Figure 1. Expression analysis of peptidoglycan recognition proteins (PGLYRPs) in porcine tissues.
PGLYRPs expression in the porcine spleen (Sp), mesenteric lymphoid nodes (MLN), and Peyer´s
patches from the ileum (iPP) or jejunum (jPP) analyzed by real-time quantitative PCR (A). The PGLYRP
mRNA expression level was normalized by using porcine β-actin mRNA and the relative index was
determined by comparison to the PGLYRP mRNA level in the spleen (1.00). Immunohistochemical
analysis of PGLYRP-3 (B) and PGLYRP-4 (C) expressions are displayed for ileal Peyer’s patches. Images
represent the expression of PGLYRPs in the whole iPP (a), in the lymphoid follicles of iPP (b), and in
the lymphoid follicle epithelium of iPP (c). The arrow indicates the presence of dendritic-like cells
with a strong expression of PGLYRP-3 or PGLYRP-4. E: epithelium, LP: lamina propria, LF: lymphoid
follicle. Values represent the means and error bars indicate the standard deviation. The results are
shown as means ± standard deviation obtained from three independent experiments (n = 6). * p < 0.05,
** p < 0.01 against spleen.
3.3. Expression Patterns of PGLYRPs in Porcine APCs of Peyer´s Patches
We next aimed to characterize the expression of PGLYRPs in different subsets of APCs isolated
from porcine PPs. We used CD172a and CD11R1 markers to define three different populations of
MHC-II+ APCs [32,37] as CD172ahighCD11R1+, CD172alowCD11R1+, or CD172alowCD11R1low cells
(Figure 2A).
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Figure 2. Expression and cellular localization of Peptidoglycan Recognition Proteins (PGLYRPs) in
antigen-presenting cells (APCs) from porcine Peyer’s patches (PPs). Flow cytometric analysis of APCs
populations from porcine PPs (A). APCs were divided into three populations using CD172a and
CD11R1 markers and PGLYRP-1, -2, -3, and -4 expressions were evaluated in the surface (B) and in the
cytoplasm (C). The results are shown as means ± standard deviation obtained from three independent
experiments (n = 6). * p < 0.05 against isotype control (iso).
Flow cytometric analysis revealed that PGLYRP-2 is strongly expressed in the cell surface of
CD172ahighCD11R1+ and CD172alowCD11R1+ cells (Figure 2B). The CD172ahighCD11R1+ population
also showed expression of surface PGLYRP-1. It was also found that the four PGLYRPs were
expressed in the intracellular compartment of CD172ahighCD11R1+ cells and that CD172alowCD11R1+
cells intracellularly expressed PGLYRP-3 and -4 (Figure 2C). The CD172alowCD11R1low cells had no
expression of PGLYRPs either on the cell surface (Figure 2B) or in the cell cytoplasm (Figure 2C).
3.4. Expression Patterns of PGLYRP in MoDCs and Their Modulation by PRR-ligands and Paraimmunobiotics
We have previously compared the immune response to microorganisms of porcine APCs originated
from PPs and MoDCs; we also observed that immature MoDCs have a similar behavior to that of
APCs from mucosal origin [32]. We, therefore, aimed herein to compare the expression of porcine
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PGLYRPs in blood monocytes and in MoDCs. Results showed that expressions of the four PGLYRPs
were significantly higher in MoDCs when compared to blood monocytes, especially for the PGLYRP-4
(Figure 3A).
Figure 3. Peptidoglycan recognition proteins (PGLYRPs) expression in porcine blood monocytes
and monocyte-derived dendritic cells (MoDCs) and their modulation by pattern recognition receptor
(PRR)-ligands and paraimmunobiotic bifidobacteria. Expressions of PGLYRPs in porcine blood
monocytes and MoDCs without stimulation (A). PGLYRPs expressions in porcine MoDCs stimulated
with PRR-ligands: zymosan (ZYM), lipopolysaccharide (LPS), muramyl tripeptide (DAP), and muramyl
dipeptide (MDP) (B). PGLYRPs expressions in porcine MoDCs stimulated with paraimmunobiotic
bifidobacteria: Bifidobacterium longum subsp. longum BB536 or B. breve M-16V (C). PGLYRP mRNA
expression level was normalized using the porcineβ-actin mRNA, and the relative index was determined
by comparison to the PGLYRP mRNA level in monocytes or control MoDCs (1.00). Values represent
the means ± standard deviation obtained from three independent experiments (n = 6). * p < 0.05,
** p < 0.01, *** p < 0.001 against either monocytes (A), or control (B).
We evaluated the effect of different PRR-ligands on the expression of porcine PGLYRPs in MoDCs
including zymosan, LPS, DAP-containing muramyl tripeptide (DAP) and muramyl dipeptide (MDP)
which are ligands for TLR2, TLR4, NOD1, and NOD2, respectively (Figure 3B). Activation of TLR2
in porcine MoDCs significantly increased the expression of PGLYRP-2, -3 and -4 while it decreased
PGLYRP-1. TLR4 activation increased PGLYRP-2, -3 and -4 expressions (Figure 3B). In addition,
stimulation of NOD1 decreased PGLYRP-1 and increased PGLYRP-2 expression while NOD2 activation
significantly augmented the expression of the four PGLYRPs in porcine MoDCs (Figure 3B).
We also evaluated the effect of two paraimmunobiotic bifidobacteria on the modulation of
PGLYRPs expression in porcine MoDCs (Figure 3C). Stimulation of MoDCs with Bifidobacterium longum
subsp. longum BB536 or Bifidobacterium breve M-16V significantly increased the expression of the four
PGLYRPs. The most remarkable changes were observed for PGLYRP-3 and -4 expressions in the
porcine MoDCs treated with the M-16V strain.
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3.5. Expression Patterns of PGLYRPs in PIE Cells and Their Modulation by PRR-ligands
We characterized the expression patterns of PGLYRPs in PIE cells, which are cell lines that were
originally established by our group for the selection of immunobiotic candidates as well for the
evaluation of immune responses in porcine IECs [29,34,38]. Here, we evaluated the mRNA expression
levels of the four PGLYRPs in PIE cells in comparison with healthy porcine spleen tissue. It was found
that PGLYRP-3 and -4 showed high expressions compared to PGLYRP-1 and -2 (Figure 4A).
Figure 4. Peptidoglycan recognition proteins (PGLYRPs) expression in porcine intestinal epithelial (PIE)
cells and their modulation by pattern recognition receptor (PRR)-ligands. Expression of PGLYRP-1,
-2, -3, and -4 in the porcine spleen and in PIE cells without stimulation (A). Modulation of PGLYRP-1,
-2, -3, and -4 expressions in PIE cells after stimulation with eight different PRR-ligands (B). Zymosan
(ZYM) and lipoteichoic acid (LTA) were used as TLR2-ligand. Lipopolysaccharide (LPS), flagellin
(FLA), imiquimod (IMI), CL075 (CL), ODN2006 (ODN), muramyl tripeptide (DAP), and muramyl
dipeptide were used as ligands for TLR4, TLR5, TLR7, TLR8, TLR9, NOD1, and NOD2, respectively.
Expressions of PGLYRP mRNA level was normalized using the porcine β-actin mRNA, and the relative
index was determined by comparison to the PGLYRP mRNA level in non-stimulated PIE cells (1.00).
Values represent the means ± standard deviation obtained from three independent experiments (n = 6).
* p < 0.05 and ** p < 0.01 against control cells.
The capacity of different PRR-ligands to modulate the expression of PGLYRPs in PIE cells was
also evaluated. TLR2 activation in PIE cells reduced the expression of PGLYRPs. Zymosan stimulation
significantly reduced the expression of the four PGLYRPs while LTA only reduced PGLYRP-4 (Figure 4B).
NOD1 activation by DAP stimulation reduced the expression of the four PGLYRPs while NOD2
activation by MDP stimulation increased all the PGLYRPs in PIE cells (Figure 4B). Stimulation of PIE
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cells with LPS increased the expression of PGLYRP-2 and -3. Activation of TLR5 with its ligand flagellin
decreased PGLYRP-2 (Figure 4B). TLR7 activation by CL075 decreased the expression of PGLYRP-1
and -4 while TLR8 activation by Imiquimod enhanced the PGLYRP-3 and -4 expressions in PIE cells
(Figure 4B). Significant upregulation of PGLYRP-2, -3, and -4 expressions were observed when PIE
cells were treated with the TLR9 agonist ODN2006 (Figure 4B).
3.6. Modulation of PGLYRPs Expression in PIE Cells by Paraimmunobiotic Bifidobacteria
The effect of the two paraimmunobiotic bifidobacteria strains on the regulation of PGLYRPs
expressions in PIE cells was evaluated. The expressions of the four PGLYRPs were increased in PIE
cells after their treatment with B. longum subsp. longum BB536 or B. breve M-16V. Of note, B. breve
M-16V was more efficient than the BB536 strain to enhance the expression of porcine PGLYRPs in PIE
cells (Figure 5).
Figure 5. Modulation of the peptidoglycan recognition proteins (PGLYRPs) expression in porcine
intestinal epithelial (PIE) cells by paraimmunobiotic bifidobacteria. PIE cells were stimulated with
paraimmunobiotic Bifidobacterium longum subsp. longum BB536 or B. breve M-16V. The qRT-PCR-based
expression of PGLYRPs mRNA level was normalized using the porcine β-actin mRNA, and the relative
index was determined by comparison to the PGLYRPs mRNA level in non-stimulated PIE cells (1.00).
The results are shown as means ± standard deviation obtained from three independent experiments
(n = 6). * p < 0.05 against control or against the indicated experimental group.
We further explored the potential interactions between PRRs ligands and the two bifidobacteria
strains in the modulation of PGLYRPs expressions in PIE cells. For this purpose, the epithelial cells were
first exposed to BB536 and M-16V strains followed by treatments with zymosan, LPS or MDP. BB536 or
M-16V treatments did not change the expressions of PGLYRP-1, -2, or -4 in PIE cells stimulated with
zymosan. However, both paraimmunobiotics increased PGLYRP-3 expression PIE cells after zymosan
treatment (Figure 6). Bifidobacteria had no effects on the expressions of PGLYRP-3 and -4 in PIE cells
after LPS stimulation. M-16V strain increased the expression of PGLYRP-1 and-2 while B536 strain
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increased only PGLYRP-1 after the stimulation of PIE cells with LPS. Both bifidobacteria increased
PGLYRP-1 and -2 and, decreased PGLYRP-3 and -4 expressions n PIE cells after NOD2 stimulation
(Figure 6).
Figure 6. Modulation of peptidoglycan recognition proteins (PGLYRP) expressions by the interactions
of pattern recognition receptor (PRR)-ligands and immunobiotics in porcine intestinal epithelial (PIE)
cells. The PIE cells were pre-stimulated with Bifidobacterium longum subsp. longum BB536 or B. breve
M-16V followed by the stimulation with zymosan (ZYM), lipopolysaccharide (LPS) or Muramyl
dipeptide (MDP). PGLYRP mRNA expression level was normalized with the porcine β-actin mRNA,
and the normalized fold expression was determined in comparison to the PGLYRP mRNA level of
non-stimulated PIE cells. The results are shown as means ± standard deviation obtained from three
independent experiments (n = 6). * p < 0.05 against control or against the indicated experimental group.
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3.7. Modulation of PGLYRPs Expression by Paraimmunobiotics in PRR-knockdown PIE Cells
In order to evaluate the effect of the interactions between paraimmunobiotic bifidobacteria and
PRRs in the modulation of PGLYRPs expressions in PIE cells, we next generated knockdown PIE cells
for four PRRs: TLR2, TLR4, NOD1, or NOD2. The RNA interference technology was employed to
knockdown each PRR’s expression in PIE cells using specific siRNAs with high inhibition capacity.
For each receptor, three different siRNAs were used to transfect PIE cells and the knockdown of PRR’s
expression was evaluated by qRT-PCR. In addition, the abolishment of PRR´s function was evaluated by
studying the induction levels of intracellular Ca2+ fluxes after specific ligand treatment (Supplementary
Figure S1A–D). The induction of intracellular Ca2+ fluxes was evaluated by recording the fluorescence
intensity. Interestingly, the ability of B. breve M-16V to increase the expression of PGLYRP-1 and 2
was significantly improved in TLR2-, TLR4-, NOD1-, and NOD2-knockdown cells (Figure 7). The
capacity of B. breve M-16V to enhance the expression of PGLYRP-4 was significantly increased in TLR4-,
and NOD2-knockdown PIE cells compared with normal PIE cells stimulated with the bacterium. The
expression of PGLYRP-3 was significantly enhanced by the M-16V treatment in all knocked down
PIE cells. An enhancement of PGLYRP-1 expression by B. longum subsp. longum BB536 stimulation
was observed in all PRR-knockdown cells. In addition, the BB536 treatment also results in enhanced
PGLYRP-2 expression in TLR2-, and TLR4-knockdown PIE cells; PGLYRP-3 expression in TLR2-, and
NOD1-knockdown PIE cells; and PGLYRP-4 expression in TLR4-, NOD1-, and NOD2-knockdown PIE
cells (Figure 7).
Figure 7. Paraimmunobiotic bifidobacteria-mediated peptidoglycan recognition proteins (PGLYRP)
expressions in pattern recognition receptor (PRR)-knockdown porcine intestinal epithelial (PIE) cells.
Porcine PGLYRP-1, -2, -3 and -4 expressions in PIE cells transfected with TLR2, TLR4, NOD1, and
NOD2 siRNA, and subsequently stimulated with Bifidobacterium longum subsp. longum BB536, or
B. breve M-16V. The porcine PGLYRP mRNA level was normalized with the porcine β-actin mRNA,
and the normalized fold expression was determined in comparison to the PGLYRP mRNA level of
non-stimulated PIE cells. The results are shown as means ± standard deviation obtained from three
independent experiments (n = 6). * p < 0.05 against control or against the indicated experimental group.
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3.8. Modulation of PRRs Expression by Paraimmunobiotics in PGLYRP-knockdown PIE Cells
Finally, we generated knockdown PIE cells for the four PGLYRPs and evaluated the effect of
paraimmunobiotic bifidobacteria in PRRs expressions. For each PGLYRP, three different siRNAs were
used to transfect PIE cells and the knockdown efficiency was evaluated by qRT-PCR-based expression
of PGLYRP genes in the transfected cells (Supplementary Figure S2A–D). Then, two successful knocked
down cell populations for each gene were used to evaluate the paraimmunobiotic bifidobacteria
mediated immunomodulation. We observed that the expression of TLR2, TLR4, NOD1, and NOD2
was significantly reduced in the four PGLYPR-knockdown cell populations as compared to that of
non-transfected PIE cells (Figures 8 and 9). Interestingly, B. breve M-16V and B. longum subsp. longum
BB536 treatments increased TLR2, NOD1, and NOD2 expressions in all PGLYPR knocked down PIE
cells (Figures 8 and 9). In addition, both paraimmunobiotic bifidobacteria significantly enhanced the
expression of TLR4 in PGLYRP-1-, PGLYRP-2-, and PGLYRP-4-knockdown PIE cells. Although both
BB536 and M-16V strains increased TLR4 expression in PGLYRP-3-knockdown PIE cells, B. breve M-16V
was more efficient to induce this effect (Figure 8).
Figure 8. Paraimmunobiotic bifidobacteria-mediated expression of TLR2 and TLR4 in peptidoglycan
recognition proteins (PGLYRP)-knockdown porcine intestinal epithelial (PIE) cells. Porcine TLR2
(A) and TLR4 (B) expressions in PIE cells transfected with PGLYRP siRNAs, and stimulated with
Bifidobacterium longum subsp. longum BB536, or B. breve M-16V. Each mRNA level was normalized with
the porcine β-actin mRNA and the normalized fold expression was determined in comparison to PIE
cells with transfected negative control siRNA. The results are shown as means ± standard deviation
obtained from three independent experiments (n = 6). * p < 0.05 against control.
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Figure 9. Paraimmunobiotic bifidobacteria-mediated expression of NOD1 and NOD2 in the
peptidoglycan recognition proteins (PGLYRP)-knockdown porcine intestinal epithelial (PIE) cells.
Porcine NOD1 (A) and NOD2 (B) expressions in PIE cells transfected with PGLYRP siRNAs and
stimulated with Bifidobacterium longum subsp. longum BB536, or B. breve M-16V. Each mRNA level
was normalized by the porcine β-actin mRNA and the normalized fold expression was determined in
comparison to PIE cells with transfected negative control siRNA. The results are shown as means ±
standard deviation obtained from three independent experiments (n = 6). * p < 0.05 against control.
4. Discussion
Pigs are livestock animals of significant economic importance. In addition, because of the
anatomical and physiological similarities between pigs and humans, these animals have attracted
attention as valuable models for immunological research [39–41]. In this regard, porcine in vivo and
in vitro studies have provided insights into molecular mechanisms involved in the interaction of the
mucosal immune system with pathogenic and beneficial microbes [33,37,42]. Several innate immune
receptors possessing the ability to regulate immune responses have been identified in human and
murine intestinal mucosa [5]; PGLYRP family is one of the major classes of them. Earlier studies in
pigs showed that PGLYRP-2 is expressed constitutively in several tissues including liver, spleen, and
intestine [29]. Likewise, our previous report also revealed that PGLYRP-3 and -4 are highly expressed
in the digestive tract of newborn and adult pigs [15]. In the present study, we assessed the expression
profiles of four PGLYRPs at gene and protein levels simultaneously in porcine PP. Results demonstrated
that PGLYRP-1, PGLYRP-2, PGLYRP-3, and PGLYRP-4 are expressed in this porcine tissue. In addition,
we observed that PGLYRP-3 and -4 proteins were highly expressed in IECs, which is consistent with
the findings of previous reports conducted in humans and mice [3,8,13].
To the best of our knowledge, we are first in demonstrating that the four PGLYRPs are expressed
in the porcine APCs of both mucosal and non-mucosal origin. PGLYRPs have known to be involved
in phagocytic activity, pathogen elimination, increased monocyte activation and pro-inflammatory
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cytokine secretion [11]. The expression of PGLYRP-3 and PGLYRP-4 proteins have been detected in
murine macrophages of the spleen as well as in the macrophage-like cell line RAW264.7 [8]. Expression
of PGLYRPs have also been detected in human blood phagocytes [11]. Flow cytometric studies showed
that PGLYRP-1, PGLYRP-3, or PGLYRP-4 antibodies bound preferentially to monocytes rather than
to lymphocytes [11]. In addition, it was shown that the inflammatory response triggered by PGN
in human monocytes was increased in the presence of PGLYRP-PGN complexes compared with
PGN alone. Moreover, the presence of PGLYRP-PGN complexes diminished the anti-inflammatory
responses [11]. These findings support our speculation that PGLYRPs would have an important role in
the interaction of mucosal and non-mucosal APCs with microorganisms and their ligands and, in the
generation of immune responses in pigs.
The expressions of PGLYRPs in porcine APCs and IECs were found to be modulated by the
stimulation of different PRR-ligands. The most notable effect was observed after NOD2 activation
that induced an upregulation of the four PGLYRPs in porcine MoDCs and PIE cells. In addition,
TLR4 activation significantly increased the expression of PGLYRP-2 and -3 in MoDCs and PIE cells.
Those findings are in agreement with the findings of Uehara et al. [43], who observed that PGLYRP
expressions in human oral epithelial cells upon stimulation with different chemically synthesized
PAMPs were markedly upregulated via activation of TLR4 or NOD2. The work also reported that
TLR2 and NOD1 activation increased the expression of PGLYRPs [43]. In contrast with those results,
we observed here that stimulation of PIE cells with zymosan or NOD1 ligands significantly decreased
the expression of PGLYRP-1, -2, -3, and -4. These results imply that TLR2 and NOD1 would have
negative regulatory roles in the expression of PGLYRPs in porcine IECs. This is in line with the report
of Jang et al. [41] who showed that PGLYRP negatively regulates NOD-mediated cytokine production
in rainbow trout live cell. However, this PRR-mediated regulatory role could be cell-type specific,
since TLR2 or NOD1 stimulation has significantly increased the expression of PGLYRP-2 in porcine
MoDCs. Interestingly, the stimulation of PIE cells with zymosan significantly reduced the expression
of the four porcine PGLYRPs, while stimulation with LTA did not induce modifications in PGLYRPs.
PGLYRPs bind to bacterial PGN but may not necessarily respond to exogenous TLR2 ligands, since a
recent report revealed that neither Lys-and DAP-type PGN stimulate mouse or human innate immune
cells via TLR2 [40]. Zymosan is a crude extract of Saccharomyces cerevisiae widely used as TLR2 ligand,
while this PRR did not sense the highly purified PGN from Bacillus anthracis and Staphylococcus aureus,
though the live bacteria of both species express abundant of TLR2 ligands [40].
It was also demonstrated here that paraimmunobiotic bifidobacteria were able to increase the
expression of PGLYRPs in both MoDCs and PIE cells. The most remarkable effects of paraimmunobiotic
treatments were observed for PGLYRP-3 and -4. It is known that PGLYRP-1, -3 and -4 are bactericidal
for pathogenic Gram-positive bacteria, and bacteriostatic for most Gram-positive and Gram-negative
commensal bacteria [13]. On the other hand, PGLYRP-2 is an N-acetylmuramyl-l-alanine amidase
and is bacteriostatic in nature. Pathogenic Gram-positive bacteria, such as Listeria monocytogenes
and Staphylococcus aureus are highly sensitive to the bactericidal effects of PGLYRP-3 and PGLYRP-4
while the Gram-positive commensal bacterium Enterococcus faecalis showed much less sensitivity to
PGLYRP-mediated killing [13]. Though pathogenic bacteria (Staphylococcus aureus) led to a rapid
onset of PGLYRP-3 expression that decreased afterward, while the immunobiotic bacteria Lactobacillus
rhamnosus GG resulted in a slow but sustained expression of PGLYRP-3 [18]. On the other hand,
the immunobiotic strains Lactobacillus jensenii TL2937 and Lactobacillus rhamnosus CRL1505 were
able significantly improve PGLYRP-2 expression in PIE cells [38,44]. It is therefore conceivable that
commensal gut microbiota would be able to improve the expression of PGLYRPs in the intestinal
mucosa and increase the bactericidal activities against pathogens. The enhanced activities of PGLYRPs
would not significantly affect commensals since they develop resistance to the bactericidal mechanisms
mediated by PGLYRP-1, PGLYRP-3, and PGLYRP-4. It should be also considered that bifidobacteria
used in this work were not viable, and therefore, they would not be affected by the activities of
PGLYRPs. To investigate in vivo the effect of paraimmunobiotic bifidobacteria on porcine intestinal
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PGLYRPs expression and to evaluate whether these changes influence the resistance to intestinal
pathogens are interesting topics for future near research.
The expression of TLR2, TLR4, NOD1, and NOD2 in PGLYRP-knockdown PIE cells were
reduced but PGLYRPs expressions in PRR-knockdown PIE cells remained stable when un-stimulated
knockdown cells were compared to their respective non-transfectant control cells. These results
indicate that PGLYRPs expressions would be required for the activation and functioning of TLR2/4
and NOD1/2, while PGLYRPs activation would be independent of TLR2/4 and NOD1/2 expressions.
Surprisingly, stimulation with paraimmunobiotic bifidobacteria, particularly the M-16V strain, resulted
in a significant upregulation of PGLYRP-1, -2, and -3 expressions in the PRR-knockdown PIE cells. Mice
knockdown for any one of the four PGLYRP genes has been reported to be more sensitive to dextran
sulfate sodium (DSS)-induced colitis and dysbiosis of gut microbiota [19,20]. The main pathologic
changes by PGLYRPs-deficiency include the loss of normal colon tissue architecture due to loss of
epithelium, hyperplasia of the lamina propria, and resulting inflammation [19]. Interestingly, it was
reported that PGLYRP-2−/− and PGLYRP-3−/− mice were highly sensitive to DSS-induced colitis than
PGLYRP-1−/− and PGLYRP-4−/− mice, which had intermediate or low sensitivity, respectively [19].
Notably, PGLYRP-3−/− mice had the most significant changes in their gut microbiota whereas
PGLYRP-1−/− and PGLYRP-4−/− mice were less sensitive to colitis and had fewer alterations in
the gut microbiota [19]. Together these findings strongly suggest the potential of paraimmunobiotic
B. breve M-16V for modulating PGLYRP expression in IECs and minimizing the pathogenesis of intestinal
inflammatory diseases through beneficial modification of intestinal innate immunity via PGLYRPs.
In line with this hypothesis, it was demonstrated that administration of viable B. breve M-16V reduced
the pathological scores of necrotizing enterocolitis-related inflammation in a preterm rat model [28]
and ameliorated DSS-induced inflammation in weanling rats [45]. The in vivo demonstration that the
non-viable bacterium retains these immunomodulatory effects would be of fundamental importance
considering that it could allow its application in populations where the administration of a living
microorganism represents a potential danger, such as immunocompromised hosts.
Our results suggest that NOD2 would be involved, at least partially, in the regulatory effect
of bifidobacteria in PGLYRP expressions since the NOD2 agonist was the only PRR ligand able to
increase the expression of the four PGLYRPs in a similar trend as bifidobacteria. Both PGLYRP-3 and
NOD2 recognize the bacterial PGN and play a synergistic role in maintaining intestinal microbiota and
inflammation as PGLYRP-3−/− NOD2−/− double-knockout mice were more sensitive to DSS-colitis than
PGLYRP-3−/− or NOD2−/− single knockout animals [46]. NOD2 and PGLYRP-2 showed a synergistic
effect in the development of local inflammation in an arthritis mice model since PGLYRP2−/− NOD2−/−
mice were resistant to PGN or MDP induced arthritis [47]. Another study reported PGLYRP2−/− and
NOD2−/− double knockdown mice had an increased susceptibility to Salmonella infection as compared
with single PGLYRP2−/− knockdown mice [46], which indicate that PGLYRP2 plays a protective
role in the control of S. enterica serovar Typhimurium infection in vivo through NOD2-dependent
mechanism. It is, therefore, possible to think that the effect of paraimmunobiotic bifidobacteria would
be the result of a combination of the activation of at least two PRRs (TLR2 and NOD2) and that
the expression of the PGLYRPs would be the consequence of the interactions between these two
signaling pathways. Identification of the PRRs and signaling pathways involved in PGLYRPs regulation
by paraimmunobiotics in porcine APCs and IECs is an interesting topic for future investigations.
In addition, to find out the functional molecules present in paraimmunobiotic bifidobacteria that are
able to trigger TLR2 and NOD2 activation is of interest, therefore, to explore their roles in the regulation
of PGLYRPs expressions in the porcine IECs and APCs.
Multiple experimental studies demonstrated an increased formation of superoxide, hydrogen
peroxide, hypochlorous acid, and peroxynitrite in colonic mucosa in animal models of IBD [48]. During
the early stage of the disease process and even before the genesis of IBD, IECs were shown to produce
elevated levels of reactive oxygen and nitrogen species through the activation of NOX and iNOS
enzymes [48]. Studies in flies have demonstrated that the deletion of PGLYRPs induce the overgrowth
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of bacteria in the fly gut and promoted intestinal damage, increased proliferation of intestinal stem
cells, and dysplasia through the activation of the intestinal NADPH oxidase NOX and the generation
of reactive oxygen species [49]. On the other hand, it was reported that the deletion of NOD2 in
IECs enhance the internalization of bacteria by epithelia. This uptake of bacteria was dependent on
reactive oxygen species and MAP-kinase activity, and the increased viable intracellular bacteria in
NOD2−/− cells reflected a reduced ability to recognize and kill bacteria [50]. Then, a significant barrier
defect occurs together with PGLYRPs-NOD2 alterations in conjunction with oxidative stress that could
contribute to inflammation and development of IBD. To evaluate the potential beneficial effect of
paraimmunobiotic bifidobacteria on the oxidative stress in the context of gastrointestinal damage
mediated by PRRs-triggered inflammation is also an interesting topic for future research.
Of note, as described for other probiotic or immunobiotic properties, we found that the capacity
of paraimmunobiotic bifidobacteria of regulating PGLYRPs expressions in porcine APCs and IECs was
strain-dependent. Indeed, our results showed that B. breve M-16V was more efficient than B. longum
subsp. longum BB536 to modulate PGLYRPs in both MoDCs and PIE cells. This is consistent with our
previous results demonstrating that BB536 strain is able to activate the TLR2-NF-kB signaling pathways
more effectively than M-16V strain [35]. As we discussed earlier, our findings indicate that TLR2 would
have a negative regulatory role in the expression of PGLYRPs in porcine IECs. This is in agreement with
the observation that the bifidobacteria strain (BB536) with the higher capacity to stimulate TLR2 [35]
was the strain with the lowest ability to modulate PGLYRPs expression in PIE cells. In addition, the
suppression of TLR2 expression in PIE cells by RNA interference significantly increased the capacity of
M-16V to up-regulate the expression of PGLYRP-1, -2, and -3. Then, whether paraimmunobiotic B.
breve M-16V and B. longum subsp. longum BB536 has a different ability to modulate the expression of
PGLYRPs in vivo, improve resistance to infection and/or reduce the severity of intestinal inflammatory
diseases is an important topic for future investigations. In addition, comparatively assessing the
immunomodulatory capacity of viable and non-viable bifidobacteria in vivo focusing on the variations
of their effects according to the dose administered is an open question, which we propose to address in
the near future with the aim of advancing in the possible practical applications of paraimmunobiotics.
5. Conclusions
We showed in this work for the first time the expression patterns of PGLYRP-1, PGLYRP-2,
PGLYRP-3, and PGLYRP-4 in porcine IECs and APCs, and the modulation of their expression by PRRs
ligands. The analysis of the expression of PGLYRP members in porcine tissues indicates that they
would be involved in host defense against pathogens and in the maintenance of normal microbiota in
the porcine host, as it has been described for other species. Our results shed light on the impact of
some PRRs in the expression of PGLYRPs in porcine APCs and IECs, which contributes not only to
the understanding of the factors that regulate PGLYRPs expression in the porcine gut but in addition
provide the scientific basis for the use of our in vitro porcine systems as suitable models for the study
of PGLYRPs´ immunobiology. We also reported here for the first time that PGLYRPs expression
in porcine in APCs and IECs can be differentially modulated by paraimmunobiotic bifidobacteria.
These results provide evidence for the use of paraimmunobiotic bifidobacteria as an alternative for
the improvement of resistance to intestinal infections or as therapeutic tools for the reduction of the
severity of inflammatory damage in diseases in which a role of PGLYRPs-microbe interaction has
been demonstrated.
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